Samsara BioCapital, LLC 13F: Quarter-over-Quarter Portfolio Changes
Samsara BioCapital, LLC reported a disclosed portfolio value of approximately $1.2 billion in its latest SEC Form 13F-HR filing for Q2 2026, up 18.3% quarter on quarter. Over the quarter, the fund initiated 4 new positions, bought more shares in 2 holdings, trimmed 5 holdings, and exited 2 positions.
Samsara BioCapital, LLC's top buy was a new stake in Alamar Biosciences INC (ALMR) , equal to 5.5% of the disclosed portfolio. Its top sell was Arcellx INC (ACLX) . The fund exited the position completely after it had accounted for 0.7% of the previous portfolio.
New PositionsQ2 2026
Securities disclosed for the first time in Q2 2026 that were not present in the prior 13F-HR filing.
| Company | Ticker | Initial Portfolio Weight | History |
|---|---|---|---|
| ALAMAR BIOSCIENCES INC | ALMR | 5.5% | History → |
| PARABILIS MEDICINES INC | PBLS | 1.3% | Holders → |
| ARTIVA BIOTHERAPEUTICS INC | ARTV | 0.8% | Holders → |
| ELOXX PHARMACEUTICALS INC | ELOX | 0.5% | Holders → |
Top BuysQ2 2026
The fund's top buys among existing positions in Q2 2026. Ranked by portfolio-weight impact, with the percentage of additional shares shown separately.
| Company | Ticker | Portfolio Weight Change | More Shares | History |
|---|---|---|---|---|
| RANI THERAPEUTICS HLDGS INC | RANI | +0.0% | +22.0% | Holders → |
| INVENTIVA SA | IVA | +-0.8% | +21.6% | History → |
Top SellsQ2 2026
The fund's top sells among positions it retained in Q2 2026. Ranked by portfolio-weight impact. Full exits are listed separately.
| Company | Ticker | Portfolio Weight Change | Shares Sold | History |
|---|---|---|---|---|
| UPSTREAM BIO INC | UPB | -0.4% | 51.9% | Holders → |
| JADE BIOSCIENCES INC | JBIO | 0.0% | 24.0% | Holders → |
| X4 PHARMACEUTICALS INC | XFOR | -0.2% | 23.8% | Holders → |
| ABIVAX SA | ABVX | -0.0% | 2.6% | Holders → |
| KALARIS THERAPEUTICS INC | KLRS | -3.0% | 0.5% | History → |
Full ExitsQ2 2026
Positions present in the prior 13F-HR filing that no longer appear in Q2 2026.
| Company | Ticker | Last-Reported Portfolio Weight |
|---|---|---|
| ARCELLX INC | ACLX | 0.7% |
| PALVELLA THERAPEUTICS INC NE | PVLA | 0.5% |
Net Portfolio Value ChangeQ2 2026
- $1.0BPrior quarter
- $1.2BCurrent quarter
- +$0.2BNet delta
- +18.3%% change
Methodology & FAQ
How Samsara BioCapital, LLC Quarterly Changes Are Computed
All deltas are sourced from sequential SEC Form 13F-HR filings for Samsara BioCapital, LLC: each row joins the most recent filing against the immediately preceding quarterly filing for the same fund. Share-count changes reflect reported trading activity, while portfolio weights can also move because of market price changes. Portfolio weights are normalized to exclude listed options for comparability. A complete description, including how confidential treatment filings are handled, is documented in the Methodology.
What stocks did Samsara BioCapital, LLC buy in Q2 2026?
In Q2 2026, Samsara BioCapital, LLC initiated 4 new positions (ALAMAR BIOSCIENCES INC (ALMR), PARABILIS MEDICINES INC (PBLS), ARTIVA BIOTHERAPEUTICS INC (ARTV), ELOXX PHARMACEUTICALS INC (ELOX)); bought more shares of RANI THERAPEUTICS HLDGS INC (RANI), INVENTIVA SA (IVA).
What stocks did Samsara BioCapital, LLC sell in Q2 2026?
In Q2 2026, Samsara BioCapital, LLC fully sold 2 positions (ARCELLX INC (ACLX), PALVELLA THERAPEUTICS INC NE (PVLA)); reduced holdings in UPSTREAM BIO INC (UPB), JADE BIOSCIENCES INC (JBIO), X4 PHARMACEUTICALS INC (XFOR), ABIVAX SA (ABVX), KALARIS THERAPEUTICS INC (KLRS).
Which positions did Samsara BioCapital, LLC initiate in Q2 2026?
Samsara BioCapital, LLC established 4 new positions in Q2 2026: ALAMAR BIOSCIENCES INC (ALMR, 5.5%), PARABILIS MEDICINES INC (PBLS, 1.3%), ARTIVA BIOTHERAPEUTICS INC (ARTV, 0.8%), ELOXX PHARMACEUTICALS INC (ELOX, 0.5%).
Which existing positions saw the largest allocation increases for Samsara BioCapital, LLC in Q2 2026?
Of 2 existing positions with share-count increases in Q2 2026, the largest were: RANI THERAPEUTICS HLDGS INC (RANI, +0.0% weight, +22.0% shares), INVENTIVA SA (IVA, +-0.8% weight, +21.6% shares).
Which positions did Samsara BioCapital, LLC fully exit in Q2 2026?
Samsara BioCapital, LLC fully exited 2 positions in Q2 2026: ARCELLX INC (ACLX, last-reported weight 0.7%), PALVELLA THERAPEUTICS INC NE (PVLA, last-reported weight 0.5%).
Which existing positions saw the largest allocation reductions for Samsara BioCapital, LLC in Q2 2026?
Of 5 existing positions with share-count reductions in Q2 2026, the largest were: UPSTREAM BIO INC (UPB, -0.4% weight, -51.9% shares), JADE BIOSCIENCES INC (JBIO, 0.0% weight, -24.0% shares), X4 PHARMACEUTICALS INC (XFOR, -0.2% weight, -23.8% shares), ABIVAX SA (ABVX, -0.0% weight, -2.6% shares), KALARIS THERAPEUTICS INC (KLRS, -3.0% weight, -0.5% shares).
Do quarter-over-quarter 13F allocation changes constitute explicit trading signals?
No. Quarter-over-quarter changes reflect a combination of active trading and market price movement. A weight increase can result from price appreciation alone, without the manager adding shares. Share-count delta is the cleaner indicator of explicit trading activity. All deltas on this page are sourced from sequential SEC Form 13F-HR filings.